RxDoctor Payments Data

Raymond Rodriguez, MD

Cardiovascular Disease · Key West, FLNPI 1578511093

Payments from drug & device makers

$782in general payments, 2019–2025

Across 26 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$146
  • E.r. Squibb & Sons, L.L.C.$119
  • Boston Scientific$119
  • Novartis$92
  • Edwards Lifesciences$77
  • Pfizer$63
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$782 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$580,926
Medicare patients
1,075
Services billed
5,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban450$574,908
EntrestoSacubitril/Valsartan131$190,915
Repatha SureclickEvolocumab64$85,126
XareltoRivaroxaban61$83,156
JardianceEmpagliflozin37$51,779
BrilintaTicagrelor31$29,469
VascepaIcosapent Ethyl23$13,523
Praluent PenAlirocumab11$12,170
Metoprolol Succinate397$6,693
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,536
Ezetimibe159$5,583
Atorvastatin Calcium471$5,417
Rosuvastatin Calcium271$4,614
Potassium Chloride45$4,422
Valsartan109$3,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$574,908450 claims
NovartisEntresto$92$190,915131 claims
Johnson & JohnsonXarelto$41$83,15661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →